ImmunoTranscriptomic platform combines identification of immune cell mRNA signatures with AI for early cancer detection LAUSANNE, SWITZERLAND - 07:00 CET, May 13, 2019 - Novigenix SA, a leading ImmunoTranscriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Dr. Jan Groen to the position of Chief
Agreement significantly increases access to Colox® in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017 – Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC). Dr Risch is a successful and science-driven clinical laboratory organization with a strong foothold
Data validate blood-based test’s ability to detect colorectal cancer early and reliably LAUSANNE, Switzerland, May 9, 2015 – Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with
LAUSANNE, Switzerland, February 12, 2015 – Molecular diagnostics company Novigenix SA announced today it acquired Colox®, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland. Novigenix aims to increase the availability of Colox